Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29147614
Publication Date : //

Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.


Although promising, the clinical benefit provided by dendritic cell (DC)-based vaccines is still limited and the choice of the optimal antigen formulation is still an unresolved issue. We have developed a new DC-based vaccination protocol for aggressive and/or refractory lymphomas which combines the unique features of interferon-conditioned DC (IFN-DC) with highly immunogenic tumor cell lysates (TCL) obtained from lymphoma cells undergoing immunogenic cell death. We show that treatment of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) cell lines with 9--retinoic acid and IFNα (RA/IFNα) induces early membrane exposure of Calreticulin, HSP70 and 90 together with CD47 down-regulation and enhanced HMGB1 secretion. Consistently, RA/IFNα-treated apoptotic cells and -TCLs were more efficiently phagocytosed by DCs compared to controls. Notably, cytotoxic T cells (CTLs) generated with autologous DCs pulsed with RA/IFNα-TCLs more efficiently recognized and specifically lysed MCL or DLBCL cells or targets loaded with several HLA-A*0201 cyclin D1 or HLA-B*0801 survivin epitopes. These cultures also showed an expansion of Th1 and Th17 cells and an increased Th17/Treg ratio. Moreover, DCs loaded with RA/IFNα-TCLs showed enhanced functional maturation and activation. NOD/SCID mice reconstituted with human peripheral blood lymphocytes and vaccinated with autologous RA/IFNα-TCL loaded-IFN-DCs showed lymphoma-specific T-cell responses and a significant decrease in tumor growth with respect to mice treated with IFN-DC unpulsed or loaded with untreated TCLs. This study demonstrates the feasibility and efficacy of the use of RA/IFNα to generate a highly immunogenic TCL as a suitable tumor antigen formulation for the development of effective anticancer DC-based vaccines.

Authors : Montico B , Lapenta C , Ravo M , Martorelli D , Muraro E , Zeng B , Comaro E , Spada M , Donati S , Santini S M , Tarallo R , Giurato G , Rizzo F , Weisz A , Belardelli F , Dolcetti R , Dal Col J ,

Related products :

Catalog number Product name Quantity
26-671 DPPA2 may play a role in maintaining cell pluripotentiality. ECSA_DPPA2 is a promising target for antigen-specific immunotherapy in non-small cell lung cancers. 0.05 mg
'CS20-00-002 Human Lymphoma tissue array (Diffuse large cell B-cell T-cell Hodgkin lymphoma follicular diffuse B-cell, etc.) tissues 7 x 9
'CS20-00-003 Human Lymphoma tissue array (Plasmacytic lymphoma B-cell Large B-cell Burkitts lymphoma T-lymphoblastoma, etc.) tissues 7 x 9
25-256 BTBD10 appears to behave as a suppressor of cell death including neuronal cell death related to amyotrophic lateral sclerosis and an enhancer of cell growth via its positive regulation of Akt phosphor 0.05 mg
EIAAB41372 CTCL-associated antigen HD-CL-09,Cutaneous T-cell lymphoma-associated antigen HD-CL-09,Dendritic cell-derived protein kinase,DPK,hKFC-A,Homo sapiens,Human,JIK,JNK_SAPK-inhibitory kinase,Jun kinase-inh
ASC-ASKHZ-0002 Stem cell research and differentiation: G4 Dendritic Cell Generation Kit (Recombinant Human Cell Expressed Cytokines) 500 mL
ASC-ASKHZ-0001 Stem cell research and differentiation: G4 Dendritic Cell Generation Kit (Recombinant Human Cell Expressed Cytokines) 100 mL
ASC-ASKHZ-0002 Stem cell research and differentiation: G4 Dendritic Cell Generation Kit (Recombinant Human Cell Expressed Cytokines) 500 mL
ASC-ASKHZ-0001 Stem cell research and differentiation: G4 Dendritic Cell Generation Kit (Recombinant Human Cell Expressed Cytokines) 100 mL
EIAAB07400 Bos taurus,Bovine,Cell death activator CIDE-B,Cell death-inducing DFFA-like effector B,CIDEB
EIAAB07399 Cell death activator CIDE-A,Cell death-inducing DFFA-like effector A,Cidea,Mouse,Mus musculus
EIAAB07402 Cell death activator CIDE-B,Cell death-inducing DFFA-like effector B,Cideb,Mouse,Mus musculus
EIAAB07398 Cell death activator CIDE-A,Cell death-inducing DFFA-like effector A,CIDEA,Homo sapiens,Human
EIAAB07401 Cell death activator CIDE-B,Cell death-inducing DFFA-like effector B,CIDEB,Homo sapiens,Human
18-661-15049 Cell death activator CIDE-A - Cell death-inducing DFFA-like effector A Polyclonal 0.1 mg
18-661-15050 Cell death activator CIDE-B - Cell death-inducing DFFA-like effector B Polyclonal 0.1 mg
18-661-15048 Cell death activator CIDE-A - Cell death-inducing DFFA-like effector A Polyclonal 0.1 mg
M1745 MarkerGene™ Fluorescent No-Wash Cell Count Normalization Kit, Provides a simple and ultrasensitive method of measuring cell number for medium to high-throughput cell-based assays, 1 kit
MCA2248C DENDRITIC CELL EXCLUSION COCKTAIL RPE_Cy5, Product Type Monoclonal Antibody Panel, Specificity DENDRITIC CELL EXCLUSION COCKTAIL, Target Species Human, Host Mouse, Format RPE_CY5, Isotypes IgG, 50 TESTS
18-001-30077 Cell death activator CIDE-3 - Cell death-inducing DFFA-like effector protein C; Fat-specific protein FSP27 homolog Polyclonal 0.1 mg
LF-PA0178 anti-Bcl-2(B cell lymphoma 2), Rabbit polyclonal to Bcl-2(B cell lymphoma 2), Isotype IgG, Host Rabbit 100 ul
ASKHZ-0001 G4 Dendritic Cell Generation Kit (Recombinant Human Cell Expressed Cytokines) 100 mL
ASKHZ-0002 G4 Dendritic Cell Generation Kit (Recombinant Human Cell Expressed Cytokines) 500 mL
YSRTMCA1657T CD1a, Cort. Thym., B_Cell (subset), Langerhans Cell, Dendritic Cell, Clone 010, Mab anti_Human 1 ml.
YSRTMCA949 Mouse Dendritic Cell, Interdigitating Cell, Thymic Epithelium, DEC 205, Clone NLDC 145, Rat Mab anti_; frozen, IH_flow 2 ml.


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur